Advertisement

Topics

Latest Drug Discovery NewsRSS

10:42 EST 20th November 2017 | BioPortfolio

Cellular Dynamics International Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 17102017] Prices from USD $250

SummaryCellular Dynamics International Inc CDI, a subsidiary of Fujifilm Holdings Corp is a biotechnology company that develops and manufactures fully functioning human cells in industrial quantities to precise specifications. The company's products include icell cardiomyocytes, icell endothelial cells, icell hepatocytes, icell neurons, icell prototypes and mycell products. It also offers Mycell p...

Medtronic Announces FDA Approval and U.S. Launch of Next Generation Pacemakers

Azure(TM) with BlueSync(TM) Technology Improves Device Longevity and Provides Automatic, Wireless Remote Patient Monitoring DUBLIN - November 20, 2017 - Medtronic plc (NYSE: MDT) today announced U.S. Food and Drug Administration (FDA) approval and U.S. commercial launch for its portfolio of Azure(TM) pacemakers with BlueSync(TM)technology. Available in both single chamber and dual ...

Global and Regional Amebocyte Lysate Market Research Report 2017 [Report Updated: 08112017] Prices from USD $3500

SummaryAmebocyte Lysate is an aqueous extract of blood cells from the Atlantic horseshoe crab or oriental horseshoe crab. Amebocyte Lysate reacts with bacterial endotoxin lipopolysaccharide LPS, which is a membrane component of gram negative bacteria. This reaction is the basis of the Amebocyte Lysate test, which is then used for the detection and quantification of bacterial endotoxins.Market Segm...

Global Cytotoxic Drug Market Data List by Segment 20152022 [Report Updated: 07112017] Prices from USD $800

SnapshotCytotoxic drugs inhibit or prevent the function of cells. Cytotoxic drugs are primarily used to treat cancer, frequently as part of a chemotherapy regime. Recently, their uses have expanded to treat certain skin conditions e.g., psoriasis, rheumatoid and juvenile rheumatoid arthritis, and steroidresistant muscle conditions. The most common forms of cytotoxic drugs are known as antineoplast...

NuCana plc to Participate in the Evercore ISI Biopharma Catalyst / Deep Dive Conference

EDINBURGH, United Kingdom, Nov. 20, 2017 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq:NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying its ProTide(TM) technology to transform some of the most widely prescribed chemotherapy agents into more effective and safer medicines, announced today that Hugh S. Griffith, Ch...

AJCC Confirms MammaPrint’s Clinical Utility for Treatment Decisions and Staging in Recent 8th Edition Breast Chapter Update

Update clarifies that the patient and clinician may choose any genomic profile or multigene panel based on available clinical evidence at the time of treatment In line with recent publications from NEJM and ASCO, the AJCC now recognizes MammaPrint with Level I evidence for determining clinical prognosis, which is the basis f...

Science Exchange Announces Outsourced R&D Partnership with Alector

Science Exchange, the world’s leading and most secure enterprise platform and aggregator for outsourced research and development (R&D), today announced a strategic partnership with Alector, a biotech company pioneering the discovery & development of immuno-neurolog

STAT Plus: Pharmalittle: Roche scores two big trial wins; the secret EMA vote is today

Roche announced two clinical trial wins notably, its Tecentriq immunotherapy made advances against lung cancer when mixed with other treatments.

Eleven Biotherapeutics Reports Third Quarter 2017 Financial Results

-- Phase 3 Enrollment on Track to Complete in Q1 2018 -- -- Topline 3-Month Data from Phase 3 Trial of Vicinium™ on Track for Mid-2018 -- -- Strengthened Balance Sheet with $8.0 million Capital Raise -- Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing novel product candidates based on its ...

Global Medical Devices Company, MEL MEDICAL Enterprises, Modernizes Clinical Research with Multi-Year Medidata eTMF Agreement

Company Accelerates Bladder Cancer Research by Unifying Content, Data, and Workflows Medidata (NASDAQ: MDSO), the leading global provider of cloud-based solutions and data analytics for clinical research, today announced that

Prognomix Inc Product Pipeline Analysis, 2017 Update [Report Updated: 22092017] Prices from USD $750

SummaryPrognomix Inc Prognomix is a personalized medicine company that develops molecular diagnostic test for detection of risks to develop renal, ocular, cardiac, cerebral, vascular and other complications of diabetic disease. The company's products include PGX IR01, PGx GR01, PGx CD01, PGx IR02. Its PGx CD01 is an in vitro molecular companion diagnostic product used for the treatment of cardiova...

Wheat gene discovery could fend off deadly stem rust pathogen threatening global food security

USDA expects quick approval for genetically engineered virus to combat citrus greening disease in Florida

Biodesy Delta System Enables Researchers to Discover Novel Mechanism Involved in Infectious Disease

Nature Communications publication highlights new applications for highly-sensitive SHG technology Biodesy, Inc., a leader in next-generation technologies measuring structure and structural changes at the molecular level, today announced that its Delta® System was used to discover a novel mechanism involved in the earliest steps of viral infection. The...

Aimmune Therapeutics to Host Investor Symposium on Peanut Allergy Treatment with Leading Expert Allergists on Friday, December 1

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it will host an Investor Symposium in New York City on December 1, 2017. The event will bring together leading expert allergists to discuss the emerging treatment landscape in peanut allergy. Topics...

Boehringer Ingelheim Makes Many of Its Best Molecules Openly Available to the Scientific Community Via opnMe.com To Unlock Their Full Potential

opnME.com provides scientists with many best-in-class tool molecules supported by comprehensive data packages on one centralized platform for researchers to use The platform offers direct access to molecules for independent research as well as other molecules for partnering with Boehringer Ingelheim. Boehri...

Essential Thrombocythemia Pipeline Review, H2 2017 [Report Updated: 31102017] Prices from USD $2000

Essential Thrombocythemia Pipeline Review, H2 2017SummaryGlobal Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Essential Thrombocythemia Pipeline Review, H2 2017, provides an overview of the Essential Thrombocythemia Oncology pipeline landscape.Essential thrombocythemia is a chronic myeloproliferative neoplasm in which cells in the bone marrow that produce the blood...

Prescient Therapeutics (PTX) - PTX-100 to target RhoA-mutant lymphomas

Edison Investment Research - Pharmaceutical & healthcare - Prescient Therapeutics: Prescient Therapeutics is planning a clinical trial of PTX-100 in RhoA-mutant lymphomas, a niche indication where the company could potentially conduct a pivotal study before out-licensing. It has resumed recruitment in the Phase Ib component of trials of lead anti-cancer compound PTX-200 in acute myeloid leukaemia ...

Acorda Discontinues Tozadenant Development Program

Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that it is discontinuing its clinical development program for tozadenant, an investigational treatment for Parkinson’s disease, including immediately discontinuing dosing of all participants currently enrolled in its tozadenant studies. The Company made this decision based on new information obtaine...

AVEO Announces Appointment of Nikhil Mehta, Ph.D., as Senior Vice President of Regulatory and Quality Assurance

AVEO Oncology (NASDAQ: AVEO) today announced the appointment of Nikhil Mehta, Ph.D., as Senior Vice President of Regulatory and Quality Assurance, effective November 20, 2017. In this role, Dr. Mehta will oversee all aspects of regulatory, quality and technical operations for the company’s portfolio. Dr. Mehta brings to AVEO more than 25 years of experie...

FDA Grants Breakthrough Therapy Designation and Orphan Drug Designation to PellePharm for Topical Patidegib in Gorlin Syndrome

-- PellePharm on track for a Phase 3 clinical trial in 2018 -- PellePharm, a clinical-stage biopharmaceutical company committed to targeting rare genetic dermatological conditions at the source, today announced that the U.S. Food and Drug Administration (FDA) has granted both Breakthrough Therapy Designation and Orphan Drug Designation to topical patid...

U.S. Food and Drug Administration (FDA) Grants Alnylam Breakthrough Therapy Designation (BTD) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis with Polyneuropathy

– Designation Based on Positive APOLLO Phase 3 Study – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for patisiran, an investig

Circle Pharma Announces Appointment of David Spellmeyer, PhD, as Chief Scientific Officer

Circle Pharma, Inc., a developer of macrocycle therapeutics, today announced that David Spellmeyer, PhD, has been appointed as its chief scientific officer. Dr. Spellmeyer brings over 25 years of broad industrial experience to Circle. He previously served as CTO & CIO at Nodality, CSO at Signature BioScience, Research Staff Member at IBM, as w...

PathoQuest Announces Formation of Scientific Advisory Board

Members of the Scientific Advisory Board are recognized infectious diseases, microbiology and next-generation sequencing experts. The Scientific Advisory Board will advise PathoQuest in its Research and Development efforts in metagenomics applied to infectious diseases diagnostics. PathoQuest, a life sciences leader focused on improving pathogen ...

Orphazyme A/S: Completion of the Offering and registration of share capital increase

Company announcement                                                                                               No. 12/2017 Orphazyme A/S Ole Maaløes Vej 3 DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355

Quick Search
Advertisement
 

review and buy Drug Discovery market research data and corporate reports here